American Century Companies Inc Neurocrine Biosciences Inc Transaction History

American Century Companies Inc

$156 Billion
Q1 2024

A detailed history of American Century Companies Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, American Century Companies Inc holds 227,019 shares of NBIX stock, worth $30.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

227,019

Previous 782,044 70.97%

Holding current value

$30.7 Million

Previous $103 Million 69.61%

% of portfolio

0.02%

Previous 0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $72.4 Million - $79.8 Million	-555,025 Reduced 70.97%	227,019 $31.3 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $83 Million - $104 Million	782,044 New	782,044 $103 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $8.51 Million - $10.6 Million	-90,523 Reduced 8.2%	1,013,744 $114 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $21.7 Million - $25.4 Million	242,362 Added 28.12%	1,104,267 $104 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $5.31 Million - $6.94 Million	56,405 Added 7.0%	861,905 $87.2 Million

Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $25.4 Million - $30.2 Million	-238,010 Reduced 22.81%	805,500 $96.2 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $6.38 Million - $7.47 Million	-69,322 Reduced 6.23%	1,043,510 $111 Million
Q2 2022 Aug 12, 2022	BUY	$75.79 - $100.07 $24 Million - $31.7 Million	316,984 Added 39.83%	1,112,832 $108 Million
Q1 2022 May 11, 2022	BUY	$72.45 - $94.81 $48.6 Million - $63.6 Million	670,415 Added 534.48%	795,848 $74.6 Million
Q4 2021 Feb 07, 2022	BUY	$79.65 - $106.22 $487,059 - $649,535	6,115 Added 5.12%	125,433 $10.7 Million
Q3 2021 Nov 10, 2021	SELL	$86.18 - $99.03 $962,716 - $1.11 Million	-11,171 Reduced 8.56%	119,318 $11.4 Million
Q2 2021 Aug 05, 2021	SELL	$89.43 - $102.27 $1.36 Million - $1.56 Million	-15,220 Reduced 10.45%	130,489 $12.7 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $26,971 - $36,775	-308 Reduced 0.21%	145,709 $14.2 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $4.92 Million - $6.13 Million	-56,578 Reduced 27.93%	146,017 $14 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $1.36 Million - $1.9 Million	-14,094 Reduced 6.5%	202,595 $19.5 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $4.95 Million - $7.58 Million	58,175 Added 36.7%	216,689 $26.4 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $5.6 Million - $8.48 Million	-74,509 Reduced 31.97%	158,514 $13.7 Million
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $594,927 - $812,678	6,854 Added 3.03%	233,023 $25 Million
Q3 2019 Nov 13, 2019	BUY	$83.82 - $101.5 $28,163 - $34,104	336 Added 0.15%	226,169 $20.4 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $2.9 Million - $3.67 Million	40,185 Added 21.65%	225,833 $19.1 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.6 Million - $3.43 Million	37,507 Added 25.32%	185,648 $0
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $10.1 Million - $18.4 Million	148,141 New	148,141 $10.6 Million
Q3 2018 Nov 02, 2018	SELL	$98.88 - $125.85 $56.1 Million - $71.3 Million	-566,895 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$75.3 - $105.99 $5.25 Million - $7.39 Million	69,701 Added 14.02%	566,895 $55.7 Million
Q1 2018 May 03, 2018	BUY	$75.88 - $92.43 $496,710 - $605,046	6,546 Added 1.33%	497,194 $41.2 Million
Q4 2017 Feb 02, 2018	BUY	$58.53 - $77.59 $26.6 Million - $35.3 Million	454,500 Added 1257.33%	490,648 $38.1 Million
Q3 2017 Nov 01, 2017	BUY	$47.97 - $61.28 $1.73 Million - $2.22 Million	36,148	36,148 $2.22 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.

Account

American Century Companies Inc Neurocrine Biosciences Inc Transaction History